Staten biotechnology
WebDec 18, 2024 · Novo Nordisk has signed a collaboration and exclusive option agreement with Dutch drug maker Staten Biotechnology for the development of new therapies to … WebThe Next Leap in Dyslipidemia Management. Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet … Staten was founded by Prof. Alan Tall, Prof. Daniel Rader, and Dr. Paul da Silva … Board of Directors . Executive Team . Advisory Board Our lead antibody STT-5058 has recycling properties that are pH-dependent and … December 17, 2024. Staten Biotechnology B.V. and Novo Nordisk A/S announce … Staten Biotechnology B.V. Transistorweg 5J. 6534 AT Nijmegen. The Netherlands … She has for the last 15 years served as member of board of directors in a … Alan Tall, Co-founder and Advisor. Alan Tall is the Tilden-Weger-Bieler Professor of … Prior to joining Staten Biotech, Hilde served as Head of Strategic Innovation …
Staten biotechnology
Did you know?
WebDec 18, 2024 · Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will potentially receive signing and exercise fees, R&D funding, and milestone payments of up to 430 million euros. Malin Otmani WebBiotechnology. Therapeutics. Headquarters Regions European Union (EU) Operating Status Active. Last Funding Type Venture - Series Unknown. Company Type For Profit. Staten …
WebDec 18, 2024 · The Life Sciences team advised Staten Biotechnology B.V. on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidaemia. Under the collaboration agreement, Novo Nordisk will provide research and development funding and support for Staten to develop its lead asset, STT … WebMar 6, 2024 · Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, with a focus on the triglyceride space. Staten Biotechnology B.V. was incorporated in 2014 by world experts in dyslipidemia, Paul da Silva Jardine, Daniel Rader and Alan Tall. Daniela Couto is the Managing Director.
WebJul 21, 2024 · Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial. July 21, 2024, 7:00 AM UTC. Share this article. Copied WebStaten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, namely in the triglyceride space. Staten Biotechnology B.V. is incorporated …
WebDeveloper of a human monoclonal antibody intended to treat dyslipidemia. The company's antibody neutralizes apoC3, a target involved in triglyceride metabolism, enabling …
WebDec 17, 2024 · Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will... jobs in the secWebDec 18, 2024 · Novo Nordisk granted exclusive option to acquire Staten Biotechnology. The Life Sciences team advised Staten Biotechnology B.V. on its strategic collaboration with … jobs in the silver valley idahoWebAug 23, 2024 · August 23, 2024 - 1 minute. Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and … jobs in the security fieldjobs in the skateboard industryWebApr 13, 2016 · For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ … jobs in the sims 4WebMar 28, 2024 · Water in alle staten. Onderwijs. De slimme stad. Technische rating. Oververkochte aandelen. Overgekochte aandelen. Dicht bij weerstand. Dicht bij steun. Accumulatiefasen. ... ChenGuang Biotech Group Co., Ltd. heeft voor het jaar 2024 een slotdividend in contanten/10 aandelen (inclusief belastingen) van CNY 1,60000000 … insyme mediationWebDec 18, 2024 · Staten Biotechnology and Novo Nordisk have announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics … insym forewarned